Xilio Therapeutics enters into $50M ATM equity offering with Leerink Partners

Xilio Therapeutics, Inc.

Xilio entered into Sales Agreement with Leerink Partners to sell up to $50M of common stock via ATM offering.
Agent Leerink will receive 3.0% commission on gross proceeds from any shares sold under the agreement.
Sales will be made on Nasdaq Global Select Market under effective S-3 registration statement filed Nov 2022.
No minimum sales obligation; company retains discretion over timing and amount of any sales.
The ATM facility was established on March 11, 2025; either party may terminate upon written notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.